Tumor response in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by surgery

10Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Background/Aim: Neoadjuvant therapy followed by surgery is the standard treatment for advanced esophageal cancer. This study aimed to evaluated the potential of 18Ffluorodeoxyglucose positron-emission tomography to predict the pathological therapeutic effect of neoadjuvant chemotherapy. Patients and Methods: We enrolled 68 patients with advanced esophageal squamous cell carcinoma who underwent 18Ffluorodeoxyglucose positron-emission tomography before and after neoadjuvant chemotherapy, followed by surgery. Retrospective analysis of the pathological therapeutic effects was performed. Results: The pathological therapeutic effect of good responders was significantly inversely associated with the maximum standardized uptake value (SUVmax) after neoadjuvant chemotherapy and with SUVmax reduction (both p<0.0001). Univariate and multivariate analyses revealed that lower post therapy SUVmax and reduction in SUVmax were independent prognostic factors for relapse-free (p=0.02) and overall survival (p<0.0001). Conclusion: Post-neoadjuvant chemotherapy SUVmax and SUVmax reduction can predict the pathological therapeutic effect of neoadjuvant chemotherapy.

Cite

CITATION STYLE

APA

Ohsawa, M., Hamai, Y., Emi, M., Takaoki, F., Ibuki, Y., Tomoaki, K., … Okada, M. (2020). Tumor response in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by surgery. Anticancer Research, 40(2), 1153–1160. https://doi.org/10.21873/anticanres.14057

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free